CLL
Conditions
Brief summary
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Interventions
DRUGZanubrutinib
patients with treatment naive or R/R CLL who treatment with Zanubrutinib
Sponsors
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Patients aged ≥18 years old * 2\. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL \[International Workshop on Chronic Lymphocytic Leukemia\] criteria)； * 3\. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib; * 4.Prior or current use of Zanubrutinib for ≥3 months * 5.At least one follow-up was recorded during Zanubrutinib treatment
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | up to two years | PFS is defined as the duration from date of Zanubrutinib initiation to date of disease progression (PD \[according to the physician's evaluation\]) or death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | up to two years | OS is defined as the time from the starting date of Zanubrutinib to the date of death due to any cause. |
| Time to Next Therapy (TTNT) | up to two years | The TTNT will be calculated as the difference between Zanubrutinib initiation date and initiation date of the first next therapy for CLL |
| Adverse Events | up to two years | Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Special Situations |
Countries
China
Contacts
Primary ContactShenmiao Yang
Outcome results
None listed